These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18423604

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK, Hancox JC, Curtis MJ.
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T, Pollard C, Sager P.
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA.
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR, Gallacher DJ, Yan GX.
    J Pharmacol Toxicol Methods; 2016 Aug; 81():151-60. PubMed ID: 27374776
    [Abstract] [Full Text] [Related]

  • 11. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Aug; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 12. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K.
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo models for testing arrhythmogenesis in drugs.
    Carlsson L.
    J Intern Med; 2006 Jan; 259(1):70-80. PubMed ID: 16336515
    [Abstract] [Full Text] [Related]

  • 17. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL.
    Toxicol Pathol; 2006 Jan; 34(1):75-80. PubMed ID: 16507547
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Mönnig G, Osada N, Breithardt G, Haverkamp W, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.